Preparing your life sciences company to go public
By Erin Cahill, Partner, US IPO Services The number of life sciences companies raising capital through public offerings has been rising steadily for the past few …
Q2 2019 Deals Industry Insights: Megadeals in many sectors reflect interest in increasing scale
By John Potter, US Deals Sector Leader @johndpotter Anyone who says summer is slow for business isn’t watching M&A, and …
Global pharma and life sciences deals insights: Year-end 2018
A year end look at M&A in the Pharmaceutical and Life Sciences sector, and new deals setting the stage for a strong start to 2019. By Glenn …
PwC Deals in the AIRA Journal
For years, Long-Term Acute Care Hospitals (LTACHs) have been at the center of a transformation of how healthcare providers care for patients and are reimbursed for services. Now, as new patient care …
How the FASB’s new definition of a business impacts pharma/life sciences deals
By Shurjo Sen, PwC Deals Partner, Accounting Advisory In January 2017, the Financial Accounting Standards Board (FASB) issued new guidance …
Restructuring trends: What did we see in 2017 and what lies ahead for 2018?
By Steve Fleming, US Crisis and Restructuring Leader, PwC Deals In our recently released paper, Bankruptcy and Restructuring: 2017 in Review and …
Capturing deal value in Healthcare Services
By Angus Buchanan, Principal, PwC’s Deals Practice It’s no secret the healthcare market has undergone a wave of M&A activity over the past decade as service providers …
PwC’s Mid-year Deals Outlook: Slow start, but still active
Can we expect a dealmaking turnaround in 2016? Dealmaking significantly subsided in the first half of 2016 following a very active year. Equity market volatility, …
